These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35525328)

  • 1. Potential role of IP3/Ca
    Jyoti Dutta B; Singh S; Seksaria S; Das Gupta G; Bodakhe SH; Singh A
    Biochem Pharmacol; 2022 Jul; 201():115071. PubMed ID: 35525328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
    Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
    Sharma VK; Singh TG; Singh S
    Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases.
    Xiang Y; Naik S; Zhao L; Shi J; Ke H
    Med Res Rev; 2024 Jul; 44(4):1404-1445. PubMed ID: 38279990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.
    Wen RT; Liang JH; Zhang HT
    Adv Neurobiol; 2017; 17():413-444. PubMed ID: 28956341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeting cyclic nucleotide phosphodiesterases.
    Maurice DH; Ke H; Ahmad F; Wang Y; Chung J; Manganiello VC
    Nat Rev Drug Discov; 2014 Apr; 13(4):290-314. PubMed ID: 24687066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
    Keravis T; Lugnier C
    Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of PDE modulation in treating heart disease.
    Knight W; Yan C
    Future Med Chem; 2013 Sep; 5(14):1607-20. PubMed ID: 24047267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
    Tulsian NK; Sin VJ; Koh HL; Anand GS
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease.
    Domek-Łopacińska KU; Strosznajder JB
    Mol Neurobiol; 2010 Jun; 41(2-3):129-37. PubMed ID: 20213343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
    Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
    Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.
    Mehta A; Patel BM
    Life Sci; 2019 Aug; 230():150-161. PubMed ID: 31125564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
    Preedy MEJ
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.